Skip to content
Screener

Biodesix, Inc. BDSX Q3 2025 earnings

Reported November 3, 2025 · After market close

Revenue$21.8MMiss by $4.5M
EPS-$1.16Beat by $0.44
Revenue estimate$26.3M
EPS estimate-$1.60

Next report

Nov 5, 2026 (In 3 days)
Revenue estimate$27.5M
EPS estimate-$0.75

Financials

Q3 2025

Income statement

See full
Revenue$21.8M+19.9%
Operating income-$7.1M+17.9%
Net income-$8.7M+15.0%
EPS (diluted)-$1.16+17.1%

Balance sheet

See full
Cash & equivalents$16.6M-47.1%
Total debt$72.9M+17.7%
Total equity-$1.7M-106%
Total assets$88.7M-13.6%

Cash flow

See full
Operating cash flow-$8.9M+16.8%
CapEx$48.0K-79.2%
Free cash flow-$8.9M+18.1%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$60.4M-76.8%
Enterprise value$116.71M-59.9%
P/S0.8×-3.2×

Profitability

See full
Operating margin-40.6%-7.7pp
Net margin-49.3%-10.2pp
FCF margin-36.4%-13.9pp

Returns & leverage

See full
Current ratio1.8×-1.6×

Segments

By product

See full
Diagnostic Tests$19.8M+15.5%
Development Services$1.9M—

FAQ

When did Biodesix, Inc. report Q3 2025 earnings?
Biodesix, Inc. (BDSX) reported Q3 2025 earnings on November 3, 2025 after market close.
What were Biodesix, Inc.'s Q3 2025 revenue and EPS?
Biodesix, Inc. reported revenue of $21.8M and eps of $-1.16 for Q3 2025.
Did Biodesix, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $26.3M by $4.5M. EPS beat the consensus estimate of $-1.60 by $0.44.
How did Biodesix, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 19.9% from $18.2M a year earlier and eps declined 1557.1% from $-0.07.
Where can I find Biodesix, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-262508) and the 10-Q periodic report (0001193125-25-262532) directly on SEC EDGAR. The filing index links above go to sec.gov.